A carregar...
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF)-A, a key player in the angiogenesis pathway. Despite benefits of bevacizumab in cancer therapy, it is clear that the VEGF pathway is complex, involving multiple isoforms, receptors, and alternat...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3685399/ https://ncbi.nlm.nih.gov/pubmed/23807861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S45193 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|